Rational polytherapy with lacosamide in clinical practice: Results of a Spanish cohort analysis RELACOVA

详细信息	查看全文 | 推荐本文 |

• 作者：Vicente Villanueva^a ; ^{villanueva_vichab@gva.es} ; Elena L&oacute ; pez-Gomá ; riz^b ; Javier L&oacute ; pez-Trigo^c ; Juan Palau^a ; Manuel Garcí ; a^a ; Teresa Villarroya^d ; Macarena Bonet^d ; Consuelo Santafé ; ^e
• 关键词：Partial onset epilepsy ; Refractory epilepsy ; Lacosamide ; Antiepileptic drug ; Sodium channel blocker ; Observational study ; Polytherapy
• 刊名：Epilepsy & Behavior
• 出版年：2012
• 期刊代码：76_15255050
• 类别：neu
• 出版时间：March, 2012
• 卷：23
• 期：3
• 页码：298-304
• 文件大小：403 K

摘要

There has been little long-term success with polytherapy for patients with refractory partial-onset epilepsy. The rational combination of antiepileptic drugs based on their mechanism of action may help improve treatment efficacy and tolerability. Lacosamide, a novel sodium channel blocker (SCB), was investigated in 158 patients with partial-onset epilepsy in the prospective, multicenter, observational, RELACOVA cohort study conducted in Spain. After 12 months' treatment with lacosamide, 47%of patients were responders (鈮?#xA0;50%reduction in seizure frequency) and 24%were seizure free. Lacosamide was well tolerated; dizziness was the most frequent adverse event. Efficacy was better (responder rate, 65%vs 38%; seizure free rate, 35%vs 17%) and there was a lower adverse event rate (33%vs 58%) in patients receiving non-SCBs (n = 49) versus those receiving SCBs (n = 104) as concomitant therapy at baseline. Further investigation of lacosamide combination therapy is warranted.